Showing results (1521-1530 of 1,583) with videos related to
Sort By:
Pageof 159
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2020
Parental benefits and offspring costs reflect parent-offspring conflict over the age of fledging among songbirdsTodd M Jones, Jeffrey D Brawn, Ian J Ausprey, et al.Virology Journal|December 18, 2025
Circulation dynamics of West Nile virus in Germany, 2023 and 2024Anne Schwarzer, Franziska Schopf, Martin H Groschup, et al.Nature Communications|August 11, 2017
The non-coding RNA landscape of human hematopoiesis and leukemiaAdrian Schwarzer, Stephan Emmrich, Franziska Schmidt, et al.Molecular Systems Biology|July 8, 2020
Dual lysine and N-terminal acetyltransferases reveal the complexity underpinning protein acetylationWilly V Bienvenut, Annika Brünje, Jean-Baptiste Boyer, et al.Translational Psychiatry|January 8, 2021
Biallelic mutations in the death domain of PIDD1 impair caspase-2 activation and are associated with intellectual disabilityTaimoor I Sheikh, Nasim Vasli, Stephen Pastore, et al.Antimicrobial Agents and Chemotherapy|March 10, 2022
An Optimized Dihydrodibenzothiazepine Lead Compound (SBI-0797750) as a Potent and Selective Inhibitor of Plasmodium falciparum and P. vivax Glucose 6-Phosphate Dehydrogenase 6-PhosphogluconolactonaseIsabell Berneburg, Satyamaheshwar Peddibhotla, Kim C Heimsch, et al.Plos One|March 14, 2012
The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trialCaterina Guinovart, Carlota Dobaño, Quique Bassat, et al.Cellular and Molecular Life Sciences : CMLS|November 13, 2025
Super-enhancer profiling reveals ThPOK/ZBTB7B, a CD4<sup>+</sup> cell lineage commitment factor, as a master regulator that restricts breast cancer cells to a luminal non-migratory phenotypeCamila D Arcuschin, Kamin Kahrizi, Rosalyn W Sayaman, et al.Journal of Cancer Research and Clinical Oncology|September 19, 2013
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failureWolfram Pönisch, Barbara Moll, Malvina Bourgeois, et al.Journal of Cancer Research and Clinical Oncology|January 12, 2021
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang, et al.Pageof 159